Synagis Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of rsv infections in infants, growing awareness of preventive monoclonal therapies, expansion of neonatal intensive care units, availability of reimbursement for rsv prophylaxis, regulatory approvals for pediatric biologics.

The growth in the forecast period can be attributed to rising investments in next-generation rsv prevention therapies, increasing focus on long-acting monoclonal antibodies, expansion of biologic manufacturing capacity, growing pediatric healthcare expenditure, increasing adoption of precision immunotherapy approaches. Major trends in the forecast period include increasing adoption of monoclonal antibody-based rsv prophylaxis, rising focus on preventive pediatric immunotherapies, expansion of cold-chain dependent biologic distribution, growing emphasis on high-risk infant protection, improved manufacturing scalability for biologics.

The increasing prevalence of chronic respiratory conditions is expected to drive the growth of the Synagis market going forward. Chronic respiratory conditions are long-lasting illnesses affecting the lungs and airways, causing persistent breathing difficulties. The rise in these conditions is attributed to factors such as aging populations, smoking, lifestyle choices, genetic predispositions, occupational exposures, and environmental pollution. Synagis (palivizumab) helps prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and children, reducing complications and exacerbations in those with chronic respiratory conditions. For instance, in June 2025, the World Health Organization (WHO) reported that chronic respiratory diseases affect over 80 million people, with many more cases undiagnosed, according to a joint WHO and European Respiratory Society report. Therefore, the increasing prevalence of chronic respiratory conditions is driving the growth of the Synagis market.

The rise in healthcare expenditure is further supporting the growth of the Synagis market. Healthcare expenditure includes spending on medical treatments, hospital care, medications, and preventive measures. Factors contributing to increased healthcare spending include aging populations, the growing prevalence of chronic diseases, public health challenges, and rising demand for healthcare services. Higher healthcare expenditure enables greater investment in preventive treatments for high-risk infants and children, such as Synagis. For instance, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure rose by 5.6% in nominal terms between 2022 and 2023, compared with a 0.9% increase in 2022. Therefore, the growth in healthcare expenditure is driving the Synagis market.

Major companies in the Synagis market are focusing on securing drug approvals to provide preventive therapy for RSV, addressing a significant unmet medical need. Drug approval involves regulatory evaluation of a drug’s safety, efficacy, and quality before authorization for public use. For example, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical company, received approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab as a preventive therapy for RSV. The injection is available as 100 mg/ml in single-dose vials of 50 mg/0.5 ml and is administered intramuscularly. Palivizumab is indicated for infants born at ≤35 weeks gestation, children with bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This approval marked the first preventive therapy for RSV available in India.

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB.

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the synagis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the synagis market by increasing costs of imported biologic manufacturing inputs, specialized laboratory reagents, sterile packaging materials, and cold-chain logistics equipment. North America and Europe are most affected due to dependence on cross-border biologics supply chains and imported formulation components, while Asia-Pacific faces higher distribution and storage costs. These tariffs are contributing to elevated production expenses and pricing pressures across hospital and specialty pharmacy channels. However, they are also encouraging regional biologics manufacturing investments, localized fill-finish operations, and stronger domestic cold-chain infrastructure development.

The synagis market research report is one of a series of new reports that provides synagis market statistics, including synagis industry global market size, regional shares, competitors with a synagis market share, detailed synagis market segments, market trends and opportunities, and any further data you may need to thrive in the synagis industry. This synagis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Synagis (palivizumab) is a medication used to prevent serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants and children. It is a monoclonal antibody that binds to RSV, preventing the virus from entering and infecting cells in the respiratory system.

The primary clinical indications for Synagis include RSV prophylaxis, premature infants with bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), and immunocompromised infants and children. RSV prophylaxis involves preventive measures, such as administering monoclonal antibodies like Synagis, to reduce the risk of RSV infections in high-risk infants and young children. It is available in formulations of 50 mg/0.5 ml and 100 mg/1 ml and is distributed through wholesale distributors and online retailers. Synagis is used by pediatric and adult patients.

The synagis market consists of sales of pre-filled, single-dose vials and injectable solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.